Company Overview of Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A., a radiopharmaceutical company, develops, produces, and commercializes molecular nuclear medicine diagnostic and therapeutic products primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany, and Canada. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company...
20 Rue Diesel
Saint Genis Pouilly, 01630
Founded in 2002
Key Executives for Advanced Accelerator Applications S.A.
Founder, Chief Executive Officer, President, Director and Member of R & D Steering Committee
Group Chief Financial Officer
Global Head of Pre-Clinical Research
Head of Clinical Development
Compensation as of Fiscal Year 2015.
Advanced Accelerator Applications S.A. Key Developments
Advanced Accelerator Eyes Acquisitions
Oct 1 15
Advanced Accelerator Applications S.A. is looking for acquisition opportunities. Advanced Accelerator has filed an initial public offering (IPO) in the amount of $75 million. Advanced Accelerator intend to use the net proceeds from this offering for expanding our marketing, manufacturing and commercialization capabilities for Lutathera, if it is approved by the FDA and/or EMA and organizing distribution to additional markets and geographies, in particular in the United States, clinical trials and other R&D efforts for our other principal pipeline product candidates, including Annexin V-128, and our Somakit products, expanding our manufacturing infrastructure and for general corporate purposes, including acquisitions of, or investment in businesses or assets to expand any of the above.
Advanced Accelerator Applications S.A. Announces Positive Results from Phase 3 Study NETTER-1 Evaluating Lutathera in Patients with Advanced Midgut Neuroendocrine Tumors
Sep 27 15
Advanced Accelerator Applications S.A. announced that the pivotal Phase 3 NETTER-1 study for Lutathera (177Lu-DOTATATE) met its primary endpoint of assessing progression-free survival (PFS), demonstrating that Lutathera significantly improved PFS when compared with Sandostatin LAR 60mg (Octreotide LAR) in patients with advanced midgut neuroendocrine tumors (NETs). The NETTER-1 study met its primary endpoint by demonstrating that treatment with Lutathera was associated with a statistically significant and clinically meaningful risk reduction of 79% of disease progression or death versus a treatment with a double dose of Octreotide LAR (hazard ratio 0.21, 95% CI: 0.13-0.34; p<0.0001). The median PFS in the Lutathera arm is not yet reached, whilst the median PFS in the Octreotide LAR 60 mg arm was 8.4 months. The adverse events observed on Lutathera in NETTER-1 are consistent with the results of Lutathera's previous Phase I-II study, with Lutathera demonstrating a favorable safety profile. Enrollment was completed in February 2015, with a target of 230 patients randomized (1:1) in 36 sites in Europe and 15 sites in the United States. At the time of statistical analysis, the number of centrally confirmed disease progressions or deaths was 23 in the Lutathera group and 67 in the Octreotide LAR 60 mg group. The median PFS was not yet reached for Lutathera and was 8.4 months with 60 mg Octreotide LAR [95% CI: 5.8-11.0 months], p<0.0001, with a hazard ratio of 0.21 [95% CI: 0.13-0.34]. Within the current evaluable patient dataset for tumor responses (n=201), 19 patients (19%) reported complete and partial responses (CR+PR) in the Lutathera group versus 3 (3%) in the Octreotide LAR 60 mg group (p<0.0004). Although the overall survival (OS) data is not mature enough for a definitive analysis, the number of deaths was 13 in the Lutathera group and 22 in the Octreotide LAR 60 mg group (p<0.0186 at interim analysis), which initially suggests an improvement in OS. The Phase 3 NETTER-1 study provides evidence of a clinically meaningful and statistically significant increase in PFS and objective response rate (ORR), and also suggests a survival benefit in patients with advanced midgut neuroendocrine tumors treated with Lutathera.
Advanced Accelerator Applications S.A. Presents at Citi European Healthcare Conference, Jun-15-2015
May 11 15
Advanced Accelerator Applications S.A. Presents at Citi European Healthcare Conference, Jun-15-2015 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Jordan Silverstein, Director of Investor Relations.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 23, 2015
January 8, 2015